{"id":78152,"date":"2026-09-02T15:01:19","date_gmt":"2026-09-02T07:01:19","guid":{"rendered":"https:\/\/flcube.com\/?p=78152"},"modified":"2026-09-02T15:01:19","modified_gmt":"2026-09-02T07:01:19","slug":"sino-biopharmaceuticals-cttq-grants-cipla-rights-to-tqb2102-her2-adc-in-emerging-markets-for-up-to-usd-123-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78152","title":{"rendered":"Sino Biopharmaceutical’s CTTQ Grants Cipla Rights to TQB2102 HER2 ADC in Emerging Markets for Up to USD 123 Million"},"content":{"rendered":"\n

Sino Biopharmaceutical<\/strong> (HKG: 1177<\/a>) announced that its subsidiary, Chia Tai Tianqing (CTTQ)<\/strong>, entered into an agreement with Cipla Limited<\/strong>, granting Cipla<\/strong> the rights to develop and commercialize TQB2102<\/strong> in India, South Africa, and five other emerging markets. The deal delivers an upfront payment plus potential development, regulatory, and sales milestone payments totaling up to USD 123 million, alongside tiered double-digit royalties.<\/p>\n\n\n\n

Deal Structure & Key Terms<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Licensor<\/td>Chia Tai Tianqing (CTTQ)<\/strong>, subsidiary of Sino Biopharmaceutical<\/strong> (HKG: 1177)<\/td><\/tr>
Licensee<\/td>Cipla Limited<\/strong><\/td><\/tr>
Asset<\/td>TQB2102<\/strong> \u2013 HER2 biparatopic bispecific antibody-drug conjugate (ADC)<\/td><\/tr>
Deal Type<\/td>Regional license \u2013 development and commercialization<\/td><\/tr>
Territory<\/td>India, South Africa, and five other emerging markets<\/td><\/tr>
Total Potential Value<\/td>Up to USD 123 million (upfront + development, regulatory, and sales milestones)<\/td><\/tr>
Royalties<\/td>Tiered double-digit rates based on annual net sales<\/td><\/tr>
Announcement Date<\/td>31 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n